Boehringer Ingelheim Archives

Roche’s idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market,

PureTech challenges Roche’s Esbriet in head-to-head IPF trial

https://pharmaphorum.com/news/puretech-challenges-roches-esbriet-in-head-to-head-ipf-trial/

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer’s spesolimab data raises hope for serious skin disease

Phil Taylor Boehringer Ingelheim, dermatology, Immunology and inflammation, rare disease, spesolimab 0 Comment

Fresh from being awarded a fast-track review from the FDA, Boehringer Ingelheim’s spesolimab has shown encouraging efficacy in

Boehringer’s spesolimab data raises hope for serious skin disease

https://pharmaphorum.com/news/boehringers-spesolimab-data-raises-hope-for-serious-skin-disease/

Digital/ News/ News

Boehringer invests again in AI diagnosis specialist Brainomix

Phil Taylor Boehringer Ingelheim, Brainomix, digital, digital health, fibrosis, financing, Oncology, stroke 0 Comment

UK digital health company Brainomix has raised £16 million ($21.5 million) that will be used to extend the

Boehringer invests again in AI diagnosis specialist Brainomix

https://pharmaphorum.com/news/boehringer-invests-again-in-ai-diagnosis-specialist-brainomix/

Solving the elective care conundrum through digital innovation

Digital/ News/ News

Boehringer-backed digital health academy set for launch in UK

Phil Taylor Boehringer Ingelheim, digital, digital health, NHS, ORCHA, Training 0 Comment

An online training academy that aims to raise the digital skills of NHS health and care workers is

Boehringer-backed digital health academy set for launch in UK

https://pharmaphorum.com/news/boehringer-backed-digital-health-academy-set-for-march-launch-in-uk/

R&D/ Views & Analysis/ Views and analysis

Legal requirement, ethical duty: How to develop compliant, useful lay summaries

Amanda Barrell Boehringer Ingelheim, clinical trials, EFPIA, GLP, medical writing 0 Comment

New lay summary guidelines walk sponsors through their obligations under EU regulation No. 536/2014, due to come into

Legal requirement, ethical duty: How to develop compliant, useful lay summaries

https://pharmaphorum.com/r-d/eu-regulation-develop-compliant-lay-summaries/

Patients/ Views & Analysis/ Views and analysis

Co-inspiration: Listen and learn to overcome patient-centricity barriers

Amanda Barrell Boehringer Ingelheim, patient centricity, patients 0 Comment

How can pharma move from a product- to a patient-centric mindset? By closing mouths and opening ears, according

Co-inspiration: Listen and learn to overcome patient-centricity barriers

https://pharmaphorum.com/patients/co-inspiration-listen-and-learn-to-overcome-patient-centricity-barriers/

News/ News/ Sales and Marketing

FDA clears first “interchangeable” Humira biosimilar

Phil Taylor AbbVie, biosimilar, Boehringer Ingelheim, Cyltezo, Humira, immunology, regulatory approval 0 Comment

Biosimilar competition to AbbVie’s big-selling Humira drug in the US has just been ratcheted up by the FDA

FDA clears first “interchangeable” Humira biosimilar

https://pharmaphorum.com/news/fda-clears-first-interchangeable-humira-biosimilar/

Doctor in the hand shows the scanning of the lung .

Market Access/ News/ News

NICE changes stance on Sanofi’s Dupixent for severe asthma

Phil Taylor Boehringer Ingelheim, HEOR, NHS, NICE, Ofev, rare disease, Regeneron, respiratory, Sanofi, severe asthma 0 Comment

18 months after saying “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma

NICE changes stance on Sanofi’s Dupixent for severe asthma

https://pharmaphorum.com/news/nice-changes-stance-on-sanofis-dupixent-for-severe-asthma/

News/ News/ Oncology

Boehringer buys Abexxa, bolstering its immuno-oncology pipeline

Phil Taylor abexxa, Boehringer Ingelheim, immuno-oncology, M&A, Oncology 0 Comment

Boehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area

Boehringer buys Abexxa, bolstering its immuno-oncology pipeline

https://pharmaphorum.com/news/boehringer-buys-abexxa-bolstering-its-immuno-oncology-pipeline/

Trending

Boehringer Ingelheim

Login